We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 14, 2021

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Crohn Disease

Journal of Crohn's & Colitis


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Crohn's & Colitis
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
J Crohns Colitis 2021 Aug 17;[EPub Ahead of Print], S Vermeire, G D'Haens, F Baert, S Danese, T Kobayashi, EV Loftus, S Bhatia, C Agboton, M Rosario, C Chen, W Zhang, K Kisfalvi, WJ Sandborn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading